Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer Journal Article
| Authors: | Fornier, M.; Esteva, F. J.; Seidman, A. D. |
| Article Title: | Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer |
| Abstract: | Metastatic breast carcinoma still remains an incurable condition. The relentless search for novel agents that might prove useful for management has evolved toward monoclonal antibodies, in part because of a rapidly expanding understanding of breast cancer biology. Trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA) is a recombinant humanized monoclonal antibody against the HER-2 receptor that has shown antitumor activity as a single agent in phase I and II trials of patients with metastatic breast cancer overexpressing HER-2. The observation of increased antitumor activity between trastuzumab and some chemotherapeutic agents in preclinical models has prompted its use in combination with several drugs. Of particular interest is the use of trastuzumab with paclitaxel. Two trials were presented at the 1999 meeting of the American Society of Clinical Oncology that evaluated this combination. One multicenter phase III trial showed clinical benefit and increased survival for patients with HER-2-overexpressing metastatic breast cancer treated with chemotherapy plus trastuzumab. A phase II trial, reviewed in this report, evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab for patients with metastatic breast carcinoma, including those overexpressing and nonoverexpressing HER-2. © 2000 by W.B. Saunders Company. |
| Keywords: | adult; cancer survival; aged; clinical trial; cisplatin; cancer combination chemotherapy; drug efficacy; drug safety; conference paper; capecitabine; gemcitabine; paclitaxel; gene overexpression; phase 2 clinical trial; breast cancer; antineoplastic combined chemotherapy protocols; antineoplastic activity; breast neoplasms; antibodies, monoclonal; taxoids; phase 3 clinical trial; phase 1 clinical trial; trastuzumab; navelbine; genes, erbb-2; oncogene neu; clinical trials, phase ii; humans; human; female; priority journal |
| Journal Title: | Seminars in Oncology |
| Volume: | 27 |
| Issue: | 6 Suppl. 11 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2000-12-01 |
| Start Page: | 38 |
| End Page: | 45 |
| Language: | English |
| PUBMED: | 11236027 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 18 November 2015 -- Source: Scopus |
Citation Impact
Related MSK Work